Lemtrada is a drug that is approved for patients suffering from relapsing multiple sclerosis but can have serious and often deadly side effects.

Doctors administering Lemtrada need to take special precautions

Tuesday, April 9, 2019 - The Food and Drug Administration (FDA) issued a warning in 2018 to patients taking Lemtrada multiple sclerosis (MS) medication of the risk of suffering a stroke. MS patients are reporting suffering from arterial dissection leading to stroke within 24 hours after taking a Lemtrada infusion. Lemtrada is the brand name for the drug Alemtuzumab. The warning was in response to complaints made to the Federal Adverse Event Reporting System (FAERS). The FDA forced Sanofi, maker of Lemtrada to update their package warning label to reflect the stroke risk. Lemtrada carries the most serious black box warning reserved for drugs that can cause serious injuries and sudden death in and of themselves. The FDA warns that Lemtrada can cause "arterial dissection and ischemic or hemorrhagic stroke." Lemtrada patients that have suffered a stroke should consult a Lemtrada stroke attorney to see if they qualify to file a claim against Lemtrada's manufacturer for reimbursement of medical expenses, lost wages, pain and suffering, and all other related expenses.

A cerebral arterial dissection is a tear in the lining of an artery such as those in the head and neck that carry blood to the brain. A coronary arterial dissection is a tear in the lining of the arteries leading to the heart. Both cerebral and coronary arterial dissection can lead to strokes and heart attacks respectively. Arterial dissection is usually a result of a genetic disease but can also occur due to extremely high blood pressure. Lemtrada has been linked to thirteen cases of arterial dissection since its inception in 2014, including one fatality. Other warnings listed on the Lemtrada black box include "serious, sometimes fatal autoimmune conditions, serious and life-threatening infusion reactions, and an increased risk of malignancies including thyroid cancer, melanoma, and lymphoproliferative disorders." When tears occur in the lining of the artery, blood no longer flows smoothly over the artery's inner surface and instead, fatty blood platelets accumulate on the walls. Eventually, a blood clot will break free and can become stuck in the smaller veins causing a blockage resulting in a paralyzing stroke or sudden death from heart attack. Arterial dissection was reported occurring within 24-hours of receiving a Lemtrada infusion in 12 of the 13 FDA patients and within 72-hours in the other. Blood cells start to die within the brain in minutes after being cut off from oxygen.

Doctors treating multiple sclerosis patients are urged according to the FDA to closely monitor them for at least the first 24-hours post-Lemtrada infusion and watch for the early warning signs of a stroke. Such signs include "numbness in the hands, fingers, and feet, mental fog, slurred speech, double vision, balance issues and dizziness, and severe headaches. Doctors should be alerted if they see any of these symptoms in their Lemtrada MS patients during and after administering the drug.

More Recent Lemtrada Stroke Lawsuit News:

• Lemrtrada Risks Were Worth It For One Recent Patient | 4/14/2021
• The Shocking Types of Deaths Caused By Lemtrada | 4/9/2021
• RRMS Has Different Stages With Different Symptoms | 4/5/2021
• Nurses Monitor Lemtrada (Alemtuzumab) Patients For Signs of Its Deadly Side Effects | 3/31/2021
• Lemtrada Can Cause Sudden Death And Many Other Health Issues | 3/8/2021
• Lemtrada May Slow the Progression of Relapse Remitting MS But with Potentially Severe Side Effects | 3/5/2021
• MS Doctors May Need To Be Reminded of Lemtrada's Deadly Side Effects | 3/1/2021
• Doctors Treating RRMS Must Discuss Lemtrada's Deadly Side Effects With Patients | 2/23/2021
• Lemtrada Can Cause An Arterial Dissection and Instant Death | 1/20/2021
• Lemtrada Toxicity May Cause Arterial Dissection Leading To Strokes | 1/13/2021
• People As Young As 20 Should Watch For Symptoms of Multiple Sclerosis | 12/30/2020
• Lemtrada Patients Could Be At Risk When Taking Covid-19 Vaccine | 12/15/2020
• Lemtrada Patients Have May Have Safer Options | 12/8/2020
• Stem Cell Rejection Could Complicate Future RRMS Treatments | 11/25/2020
• Breakthroughs In Stem Cell Transplantation Could Eliminate The Need For Lemtrada And Its Unpredictable Side Effects | 11/19/2020
• Lemtrada Patients Should Know Their Life Is In Danger By Taking Lemtrada | 11/9/2020
• Lemtrada Patients May Try Anything To Keep Multiple Sclerosis In Check | 11/4/2020
• Lemtrada Offers Hope For Those With Advanced RRMS | 10/13/2020
• Lemtrada Sometimes Works Well But Patients Were Only Recently Warned About The Dangers of The Drug | 10/6/2020
• Drugs Like Lemtrada May Benefit MS Patients Right From The Start | 9/29/2020
• Multiple Sclerosis Patients Suffer Fatigue Before Symptoms Gradually Increase | 9/23/2020
• Doctors May Have Dropped Lemtrada Over Covid-19 Fears | 9/2/2020
• Relapse Remitting Multiple Sclerosis Patients May Have a Promising New Drug | 8/25/2020
• Ofatumumab Could Replace Lemtrada For Treatment of Multiple Sclerosis | 8/8/2020
• RRMS Patients Have A Great Source of Information That Can Help Them Deal With Every Aspect of Their Disease | 8/4/2020
• New Information About COVID19 and Taking Lemtrada | 7/16/2020
• The Risks Of Lemtrada Therapy And Other DMTs | 7/9/2020
• Lemtrada Patients Face Possibility Of Living With The After-Effects of a Stroke | 7/6/2020
• A Multiple Sclerosis Doctor Explains The Ins and Outs of Lemtrada for RRMS Patients in a Series of YouTube Videos | 6/22/2020
• Lemtrada Carries Serious Side Effects That Come With The Potential Relief The Drug Offers | 6/1/2020
• Canadians Have One of the World's Highest Rates of Multiple Sclerosis | 5/28/2020
• RRMS Patients Explain Difficulty Managing The Disease During The Covid-19 Pandemic | 5/21/2020
• Relapse Remitting Multiple Sclerosis Patients Share Their Lemtrada Experiences Online | 5/12/2020
• Lemtrada May Also Cause ANCA Vasculitis | 4/27/2020
• Relapse Remitting Multiple Sclerosis Patients (RRMS) Should First Try Telephoning Their Doctors Before Risking Going To The Hospital Directly | 4/22/2020
• Experts Weigh In On Discontinuing Lemtrada Treatments During Pandemic | 4/10/2020
• Lemtrada Patients At Extreme Risk From COVID-19 | 4/8/2020
• Relapse-Remitting Multiple Sclerosis Patients Should Avoid Lemtrada (alemtuzumab) During The Covid-19 Pandemic | 3/20/2020
• Sanofi Forced To Pay $11.8 Million In Alleged Kick-Back Scheme | 3/16/2020
• Newly Diagnosed RRMS Patients Should Avoid Lemtrada and Look to Other Less Toxic Treatments | 3/11/2020
• Lemtrada Deaths Prompt Greater Scrutiny and Harsher Warnings | 2/27/2020
• Lemtrada Patients Dying At An Alarming Rate | 2/10/2020
• Lemtrada Patients Report Positive Experiences From Taking The Anti-MS Drug | 2/4/2020
• Lemtrada Fears May Be Overdone | 1/30/2020
• Some Patients Rave About Lemtrada's Effectiveness While Others Are Left Permanently Disabled | 1/8/2020
• One Last Lemtrada Warning for 2019 | 1/2/2020
• RRMS Patients May Try Stem Cell Therapy if Lemtrada Fails | 12/26/2019
• Lemtrada Patient's Fear of the Unknown Moderated in YouTube Testimonial Videos | 12/16/2019
• Lemtrada Side Effect Awareness Requirements | 12/11/2019
• Lemtrada is serious medication for a serious condition | 11/21/2019
• More Restrictions Placed on Multiple Sclerosis Sufferers Who Wish to Receive Lemtrada Treatment | 11/15/2019
• RRMS Patients May Look To Alternatives To Lemtrada | 11/6/2019
• Europe's Medicine Agency Increases Lemtrada Restrictions | 11/4/2019
• Understand The Pros and Cons of Lemtrada RRMS Treatments | 10/16/2019
• Lemtrada Is More Deadly Than Originally Thought | 10/10/2019
• Obesity Can Make Multiple Sclerosis Medications Less Effective | 10/2/2019
• RRMS Patients Should Consider Lemtrada's Risk of Arterial Dissection | 9/18/2019
• Multiple Sclerosis Patient Have a Difficult Decision To Make When The Disease is in its Latter Stages | 9/6/2019
• Lemtrada's Deadly Side Effects Greater Than Previously Thought | 9/2/2019
• Drug Makers Look to Mitigate Lemtrada's Life-Threatening Side Effects | 8/26/2019
• Lemtrada Relieves RRMS Symptoms Allowing Patients to Enjoy a Better Quality of Life | 8/20/2019
• Lemtrada Causes High Blood Pressure Before a Stroke Occurs | 8/6/2019
• Lemtrada Patients Report Promising Results | 8/1/2019
• The European Medicines Agency is Studying Lemtrada's Side Effects | 7/30/2019
• What To Watch For Indicating You May Have Multiple Sclerosis | 7/10/2019
• Lemtrada May Be Twice as Effective As Its Leading Competitor | 7/5/2019
• Brain Bleeding May Indicate a Lemtrada Stroke is Imminent | 6/27/2019
• Treating Multiple Sclerosis From Many Angles | 6/21/2019
• Lemtrada's Risks Exceed The Black Box Warning | 6/18/2019
• A Long-Term Study Demonstrates Lemtrada's Effectiveness and Adverse Side Effects | 6/11/2019
• A Leading Authority Finds Lemtrada Causes Brain Bleeding | 5/30/2019
• Lemtrada's Incredibly Long List of Adverse Side Effects | 5/23/2019
• The Outlook is Grim For Relapsing-Remitting Multiple Sclerosis (RRMS) Patients | 5/15/2019
• Lemtrada Forced To Update Black Box Warning To Include Chance of Stroke | 5/10/2019
• The European Medicines Agency Urges Doctors To Stop Using Lemtrada Effective Immediately | 5/4/2019
• The Pros and Cons of Lemtrada Therapy | 4/19/2019
• Europe's FDA is Reviewing Lemtrada's Stroke Side Effect | 4/15/2019
• MS Doctors Must Weigh The Benefits of Lemtrada Versus The Drug's Stroke Risks | 4/3/2019
• Individuals Suffering From RLMS Now Have a New Drug Called Mavenclad That Can Help Alleviate Seizures | 4/1/2019
• Stroke Warning Added to Lemtrada Boxed Label | 3/28/2019
• Anti MS Drug Lemtrada Carries Multiple Lethal Side Effects | 3/25/2019

No-Cost, No-Obligation Lemtrada Lawsuit Case Review If You or a Loved One Suffered from Lemtrada Stroke Complications

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.